Hetero, a leading Indian generic pharmaceutical firm and the world's largest producer of anti-retroviral drugs, on Friday said it has got the approval to make the generic version of a Hepatitis C drug.
The approval came from the Drugs Controller General of India.
The product "Sofosbuvir+Velpatasvira" will be marketed and distributed under the brand name "Velasof" in India by Hetero Healthcare Ltd, the company said in a statement.
Sofosbuvir+Velpatasvir is a two-drug fixed dose combination product that contains 400mg of Sofosbuvir and 100mg of Velpatasvir in a single tablet.
This fixed-dose combination is the generic version of Gilead's brand Epclusa, approved by US FDA to treat patients with chronic hepatitis C genotype 1 to 6, the statement said.
The product will be launched under the non-exclusive licensing agreement with Gilead Sciences Inc, which allows to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries, it added.
--IANS
ms/ruwa/
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app